Recce Pharmaceuticals up 6% on new antibiotic production milestone
Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
BLT | Ann: Upgraded FY24 earnings guidance | 15/04/24 | 0 | 64 | |||
|
|||||||
BLT | Ann: D&O Ongoing Disclosure Notice | 22/03/24 | 0 | 84 | |||
|
|||||||
BLT | Ann: Capital change notice | 22/03/24 | 0 | 53 | |||
|
|||||||
BLT | Ann: Revenue Growth and Profitable Third Quarter | 23/02/24 | 0 | 138 | |||
|
|||||||
BLT | Ann: D&O Initial Disclosure | 18/01/24 | 0 | 131 | |||
|
|||||||
BLT | Ann: Director announcement | 11/12/23 | 0 | 121 | |||
|
|||||||
BLT | Ann: New Chief Executive Appointed | 28/11/23 | 0 | 127 | |||
|
|||||||
BLT | Ann: Growth of B2B customer base in challenging conditions | 16/11/23 | 0 | 188 | |||
|
See All Discussions